By analyzing the CGGA dataset, the expression of THUMPD3 in the GBM group was not significantly changed compared with that in the LGG group, while the expression of TRMT112 in the GBM group was significantly increased compared with that in the grade II glioma group. This evidence concerns the gene THUMPD3 and central nervous system cancer.